Enzalutamide in patients with castration-resistant prostate cancer: retrospective, multicenter, real life study.
CONCLUSIONS: Our data shows an effective and safe profile of enzalutamide in a "realworld" perspective in patients with mcRPC.
PMID: 32748613 [PubMed - as supplied by publisher]
Source: Minerva Urologica e Nefrologica - Category: Urology & Nephrology Tags: Minerva Urol Nefrol Source Type: research
More News: Cancer | Cancer & Oncology | Docetaxel | Pain | Prostate Cancer | Study | Taxotere | Toxicology | Urology & Nephrology